沙美特罗替卡松(舒利迭)联合双水平气道正压通气对中重度COPD合并Ⅱ型呼吸衰竭患者生活质量的影响

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (12): 1392-1397.

沙美特罗替卡松(舒利迭)联合双水平气道正压通气对中重度COPD合并Ⅱ型呼吸衰竭患者生活质量的影响

童亚玲, 李乾兵, 徐建林, 陈俊

安庆市第一人民医院呼吸内科,安庆 246003,安徽

收稿日期:2012-06-20 修回日期:2012-11-30 发布日期:2012-12-31
作者简介:童亚玲,女,学士,副主任医师,副教授,主要从事慢性阻塞性肺疾病和肺部恶性肿瘤的临床研究和治疗。Tel: 13013186565 E-mail: tongyaling1978@163.com

Influence of the curative effect of salmeterol/fluticasone and bi-level positive airway pressure on severe chronic obstructive pulmonary disease with respiratory failure

TONG Ya-ling, LI Qian-bing, XU Jian-lin, CHEN Jun

Department of Respiratory Diseases,Anqing No.1 People's Hospital,Anqing 246002,Anhui,China

Received:2012-06-20 Revised:2012-11-30 Published:2012-12-31

摘要/Abstract

摘要： 目的: 观察予以沙美特罗替卡松(舒利迭)联合双水平气道正压通气长期治疗Ⅲ~Ⅳ级慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭患者,对患者的肺通气功能、焦虑抑郁、生活质量、COPD急性加重的次数的影响。方法: 48例病人按双水平气道正压通气是否联合连续吸入舒利迭(50 μg/500 μg),随机分为两组,观察治疗前、治疗 7 d 后及随访3个月、6个月后患者的动脉血气、肺通气功能、6 min 步行距离(6MWD)、SGRQ评分的变化及SAS评分的变化、COPD急性加重的次数。结果: 治疗后两组动脉血气(PaO₂、PaCO₂)、肺通气功能指标(FVC、FEV₁)、6 min 步行距离、SGRQ评分、SAS评分改善较治疗前明显改善 (P<0.05),以治疗组改善明显;治疗6月后治疗组COPD急性加重的次数少于对照组。结论: 沙美特罗替卡松(舒利迭)联合双水平气道正压通气长期治疗Ⅲ~Ⅳ级COPD患者能改善和延缓肺功能下降速度,能显著改善病人的SGRQ评分、SAS评分,改善病情的严重度,减少COPD急性加重的次数。

关键词: 沙美特罗替卡松, 双水平气道正压通气, 慢性阻塞性肺疾病, 呼吸衰竭, 生活质量

Abstract: AIM: To observe the curative effect of inhaling Salmeterol (50 microg)/ fluticasion (500 microg) and bi-level positive airway pressure for severe chronic obstructive pulmonary disease (COPD) with respiratory failure cases on lung function, anxiety and depression, quality of life and the times of acute exacerbation of COPD. METHODS: 48 severe COPD with respiratory failure cases were randomly divided into two groups. The therapy group received inhaling. Salmeterol/fluticasion and bi-level positive airway pressure including routine treatment.At the same time,the comparative group were given bi-level positive airway pressure including routine treatment.The arterial blood gas, lung function,six minutes walking distance (6MWD),the scores of SGRQ and SAS and the times of acute exacerbation of COPD were observed before the treatment,and 7 days,3 months,6 months after the treatment. RESULTS: The arterial blood gas, lung function,six minutes walking distance(6MWD), the scores of SGRQ and SAS and reduce the frequence of exacerbations of COPD of the treatment group and the end of 6 months.The significant differences were seen between the treatment group and the comparative group. The therapy group had better curative effect than the comparative group. CONCLUSION: The treatment of severe COPD with Respiratory failure cases inhaling. Salmeterol/fluticasion and bi-level positive airway pressure were effective.

Key words: Chronic obstructive pulmonary disease, Salmeterol/fluticasion, Bi-level positive airway pressure, Respimtory failure, Quality of life

中图分类号:

R563

童亚玲, 李乾兵, 徐建林, 陈俊. 沙美特罗替卡松(舒利迭)联合双水平气道正压通气对中重度COPD合并Ⅱ型呼吸衰竭患者生活质量的影响[J]. 中国临床药理学与治疗学, 2012, 17(12): 1392-1397.

TONG Ya-ling, LI Qian-bing, XU Jian-lin, CHEN Jun. Influence of the curative effect of salmeterol/fluticasone and bi-level positive airway pressure on severe chronic obstructive pulmonary disease with respiratory failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(12): 1392-1397.

参考文献

[1] Halpin DM, Tashkin DP.Defining disease modification in chronic obstructive pulmonary disease[J].COPD,2009,6(3):211-225.
[2] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17.
[3] Curtis JR, Patrick DL.The assessment of health status among patients with COPD[J]. Eur Respir J Suppl, 2003,41:36s-45s.
[4] Barnes NC, Qiu YS, Pavord ID, et al.Antiinflammatory effects of salmeterol /fluticasone propionate in chronic obstructive lung disease[J].Am J Respir Crit Care Med, 2006,173(7):736-743.
[5] 罗文. 沙美特罗替卡松粉治疗慢性阻塞性肺疾病缓解期的应用研究[J].浙江临床医学,2011,13(5):502-504.
[6] Zheng JP, Yang L, Wu YM,et al.The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD[J].CHEST, 2007,132(6): 1756-1763.
[7] Jenkins CR,Jones PW,Calverley PM,et al.Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized,placebo-controlled TORCH study[J].Respir Res, 2009,10(1): 59.
[8] 夏晴,戴兴凌,王汝涛,等.长期应用丙酸氟替卡松/沙美特罗治疗轻中度哮喘的临床疗效评价[J].中国临床药理学与治疗学,2006,11(6):702-705.
[9] Zheng JP,Yang L,Wu YM,et al.The efficacy and safety of combination salmeterol (50microg)/fluticasone propionate (500microg) inhalation twice daily via accuhaler in Chinese patients with COPD[J]. Chest, 2007,132(6):1756-1763.
[10] Casanova C,Celli BR,Tost L,et al.Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD[J]. Chest,2000,118(6):l582-l590.
[11] 唐洁,沈策.无创正压通气治疗对慢性阻塞性肺病患者生存质量的影响[J].临床内科杂志,2008,25(6):394-396.
[12] Budweiser S,Heinemann F,Fischer W,et al.Long-term reduction of hyperinflation in stable COPD by non-invasive nocturnal home ventilation[J].Respir Med,2005,99(10):976-984.

[1]	胡德凤，王轶虎，龙小宇，王广水. 甘麦大枣汤加减方联合认知行为干预对精神分裂症超高危人群的干预作用及对认知功能、生活质量及血清5-HT、MT、TSH水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 546-553.
[2]	白学敏，邹立考，金珍木，姜利佳. N-乙酰半胱氨酸通过调控EGFR/MAPK信号通路对慢性阻塞性肺疾病气道黏液高分泌的作用研究[J]. 中国临床药理学与治疗学, 2019, 24(10): 1120-1127.
[3]	贺筱彬，林小华，刘舜莉，欧焕娇. 血嗜酸性粒细胞水平影响慢性阻塞性肺疾病急性加重患者使用全身糖皮质激素的药物利用评价[J]. 中国临床药理学与治疗学, 2019, 24(1): 89-93.
[4]	陆亚君，黄晓颖，傅中明. 铝碳酸镁联合PPI治疗COPD合并咽喉反流的疗效及对AECOPD的预防作用[J]. 中国临床药理学与治疗学, 2018, 23(11): 1270-1275.
[5]	容国义，王淑美，唐末. 中医化痰法治疗非小细胞肺癌疗效的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(7): 787-794.
[6]	徐象威，陈银巧，朱佩祯. 阿米替林联合阿片类药物治疗中重度癌痛伴抑郁患者疗效分析[J]. 中国临床药理学与治疗学, 2017, 22(10): 1145-1151.
[7]	刘晓萍，赖香茂，王海全，陈玉梅，张冬梅. 药物整合在慢性阻塞性肺疾病合并焦虑抑郁障碍患者中的应用价值[J]. 中国临床药理学与治疗学, 2016, 21(9): 1038-1041.
[8]	韦柳萍，宋林，杨彬. 联合吸入噻托溴铵与糖皮质激素/长效β₂受体激动剂治疗稳定期慢性阻塞性肺疾病有效性和安全性的系统评价[J]. 中国临床药理学与治疗学, 2016, 21(7): 777-783.
[9]	秦玲, 袁天懿, 唐建良, 吴小炼, 费长顺. 综合干预模式对慢性主观性头晕患者情绪、睡眠及生活质量的影响[J]. 中国临床药理学与治疗学, 2016, 21(12): 1413-1418.
[10]	付霜, 周惠丹, 袁晓红, 曲丕盛. 围术期应用加巴喷丁对开胸术后慢性疼痛的影响[J]. 中国临床药理学与治疗学, 2015, 20(5): 583-586.
[11]	王月花，宋昱晨，赵美芳，沈香娣. 福多司坦治疗慢性阻塞性肺疾病稳定期的随机对照双盲试验[J]. 中国临床药理学与治疗学, 2015, 20(11): 1283-1286.
[12]	黄友明, 王安才, 查日田. 舒利迭联合茶碱对慢性阻塞性肺疾病稳定期患者肺动脉压及右心功能的观察[J]. 中国临床药理学与治疗学, 2014, 19(8): 920-925.
[13]	俞万钧, 王华英, 翁跃颂, 宋嫣瑾, 顾霄, 应华娟. 短期与长期烟草烟雾暴露小鼠中CD₄^＋Foxp3^＋调节性T细胞的变化及意义[J]. 中国临床药理学与治疗学, 2014, 19(6): 601-606.
[14]	汪辰吟, 陶秀华, 张弦, 汪电雷, 陈金佩, 杨丽丽, 曹银, 汪珊珊. 慢性阻塞性肺疾病进程与肺支气管上皮细胞MRP1功能改变的相关性研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 8-14.
[15]	骆松梅, 叶伟红, 华俊彦. 临床药师参与慢性阻塞性肺病急性加重期患者治疗的实践[J]. 中国临床药理学与治疗学, 2013, 18(9): 1014-1018.